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A low fixed dose of prothrombin complex
concentrate is cost effective in emergency reversal
of vitamin K antagonists 
The management of bleeding patients on vitamin K
antagonist (VKA) therapy is a common clinical challenge.
Current American College of Chest Physician (ACCP)
guidelines recommend the use of prothrombin complex
concentrates (PCCs) for rapid reversal of VKA-induced
coagulopathy.1
While efficacy and safety of PCC are well established for
VKA reversal, a well-defined dosing strategy is still lacking. 
Recently, we studied the effectiveness of a low fixed
dose regimen of 1040 IU F IX PCC compared to variable
dosing to counteract VKA associated emergency bleeding.2
This prospective study showed that low fixed PCC dose
was non-inferior to variable dosing in terms of clinical out-
come. In reaching the target INR, defined as INR less than
2, the fixed dose was non-inferior in patients with an ini-
tial INR below 7.5, but not in patients with a higher INR. 
An important question from both a clinical and costing
point of view is whether additional interventions were
needed in the fixed dose cohort to reach the non-inferior
outcome. The costs of additional interventions (i.e. other
blood products, invasive interventions, or more often
admission to an intensive care unit) may nullify any cost
savings to be gained from a lower PCC dose.
Therefore, we performed a cost analysis, in which we
evaluated the direct medical costs in all patients admitted
through the emergency room (ER). To prevent bias in esti-
mating the costs of VKA-related bleeds, we excluded
patients already hospitalized for other indications.
Cost-effectiveness was calculated using 2 decision tree
models (Figure 1). In model A, reaching the target INR was
modeled while model B was only based on the clinical out-
come.
Only direct medical costs during hospitalization from ER
admission to discharge or death were included. These
costs included PCC and blood transfusion, endoscopic
and/or surgical treatment, mortality, medical ward and/or
intensive care stay costs. Unit costs were based on Dutch
hospital source (year 2011 prices) and reference prices
(inflated to 2011).3
Analyses included Monte Carlo simulations, base-case
analyses and sensitivity analyses in which worst-case sce-
narios were adapted for the fixed dose parameters to pre-
vent any potentially coincidental finding. 
Cost analyses were performed in 137 patients. Their
characteristics and outcomes were comparable with the
whole population in the clinical study.
PCC costs accounted for 13% and 17% of the total hos-
pital costs in the fixed and the variable dose cohorts,
respectively.
In the majority of patients, target INR was reached with
a positive clinical outcome (N. fixed dose 50 of 59, variable
dose 64 of 78). These patients in the fixed dose cohort
more often received FFP (0.30 vs. 0.09 units/patient) but
had a shorter mean length of stay on a general medicine
ward compared to the patients in the variable dose cohort
(7 vs. 10 days). For patients who did not reach the target
INR (n. fixed dose 3 of 59, variable dose 4 of 78) an average
additional 3177 euros were spent to obtain a positive clin-
ical outcome in the fixed dose strategy compared to the
variable dose. This higher amount is mainly due to higher
RBC and FFP transfusion, more endoscopic treatments,
ICU stay and mortality in the fixed dose cohort. 
Using model A, the mean costs per patient were 5774
euros (SD 294) for the fixed and 7408 euros (SD 365) for
the variable dose, resulting in savings of 1634 euros per
patient with the fixed dose strategy (Table 1). Costs per
successfully treated patient (mean costs per patient/proba-
bility of successful treatment) were 6929 euros (SD 352)
and 9029 euros (SD 445), for fixed and variable PCC dos-
ing, respectively (P<0.001). 
Disregarding the target INR reached (model B), mean
costs per successfully treated patient were similar to those
in model A. In model B, three worst-case scenarios were
conceptualized for the sensitivity analyses. In worst-case
scenario 1, we maximized the length of stay on a general
medicine ward for patients with a positive clinical out-
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Table 1. Results of the cost-effectiveness analyses in both Model A and Model B.
Fixed dose strategy Variable dose strategy 
(N=59) (N=78)
Mean SD mean Sd
Model A
Mean costs per patient (C) 5774 294 7408 365
Probability of a successful treatment** (P) 0.83 − 0.82 −
Mean costs per successfully treated patient (C/P) 6929 352 9029 445
Model B
Mean costs per patient (C) 5759 299 7366 371
Probability of a successful treatment** (P) 0.95 − 0.90 −
Mean costs per successfully treated patient (C/P) 6062 315 8185 412
Sensitivity analyses
worst case #1 Mean costs per patient 7018 396 7392 369
worst case #2 Mean costs per patient 5816 294 7359 366
worst case #3 Mean costs per patient 5910 299 8290 439
**In model A a successful treatment is when a patient achieves both target INR and a positive clinical outcome. In model B a successful treatment is when a patient has a
positive clinical outcome, regardless of whether or not the target INR is reached. Worst case scenario #1: maximal length of stay in a medical ward for patients with a posi-
tive clinical outcome. Worst case scenario #2: maximal mortality for patients with a negative clinical outcome in both cohorts. Worst case scenario #3: maximal volume for
all parameters in patients with a negative clinical outcome.
come in the fixed dose cohort from seven days to ten days
to conform with the length of stay in the same outcome
group of the variable dosing regimen. While this analysis
increased the costs, the fixed dose strategy still remained
the less costly approach (7018 euros for fixed vs. 7392
euros for variable dose strategy; 95%CI: for cost difference
277-497; P<0.001). Two additional worst-case scenarios
assessing the impact of differences in mortality and in vol-
umes of additional interventions confirmed the robustness
of our findings.
From a clinical point of view, some notable differences
between the outcome groups were seen.
In the fixed dose cohort, a higher use of FFP was seen
which we ascribe to a direct consequence of the PCC strat-
egy. Furthermore, a lower mortality rate and shorter length
of hospital stay was seen in this cohort, which could be
either a consequence of the PCC strategy or a coincidence.
By performing sensitivity analyses, we explored the
robustness of our results regarding these differences in
which the overall conclusion constantly remained valid.
Interestingly, we did see the same trend in higher mortality
rate in the variable PCC dose regimen compared to the
low fixed dose regimen in our previous pilot study which
was performed on one Dutch hospital site.4
In summary, our cost analyses showed that a cost reduc-
tion in PCC with a low fixed dose strategy did not coincide
with a cost increase due to utilization of other treatment
options for VKA associated bleedings. Furthermore, by
treatment of these bleeding emergencies with a low fixed
PCC dose strategy, on average 1634 euros per patient to
2100 euros per successfully treated patient was saved com-
pared to a variable dosing strategy. The robustness of this
finding was confirmed in sensitivity analyses.
Costs should not be the driving force behind selecting
the right treatment. However, taking costs into account is
becoming increasingly important when choosing between
alternative therapies, especially since the use of PCC is
being explored more and more to counteract the new oral
anticoagulant therapy.
Taking into account the effectiveness of the low fixed
dose of PCC in our previous study and the cost analyses
presented, we conclude that a low fixed dose of 1040 IU
IX PCC is more cost-effective in emergency reversal of
VKA than a high variable dosing strategy. 
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